Retatrutide

Boehringer Ingelheim and Zealand Pharma have initiated three phase 3 trials for survodutide, a glucagon/GLP-1 receptor dual agonist that achieved up to 19% weight loss in phase 2 studies.

Trial participants in Eli Lilly's retatrutide study report unprecedented weight loss, with some patients losing up to 31% of body weight in just eight months, exceeding typical GLP-1 drug results.

A recent study shows retatrutide, an investigational triple agonist, led to a 22.1% weight loss over 48 weeks, surpassing existing GLP-1 drugs.

Moderna and Merck's mRNA-4157 combined with pembrolizumab significantly reduced melanoma recurrence risk by 44% compared to pembrolizumab alone, marking a leap in personalized cancer treatment.

GLP-1 receptor agonists are in high demand for obesity treatment due to their cardiovascular benefits, but supply shortages persist.